论文部分内容阅读
目的探讨VEGF受体3(VEGF receptor 3,VEGFR-3)在乳腺癌组织中的表达,分析其表达与乳腺癌临床病理因素的关系,为乳腺癌的临床治疗及预后判断提供依据。方法取2004年3月-2007月6月接受乳腺癌切除术的173例女性患者乳腺癌组织存档石蜡标本(实验组),应用组织芯片技术构建乳腺癌组织芯片,HE染色判断组织芯片质量,免疫组织化学染色观察VEGFR-3表达情况;并以同期接受乳腺良性病变切除术的19例女性患者乳腺组织存档石蜡标本作为对照(对照组)。将实验组患者按照年龄、肿瘤直径、腋窝淋巴结转移情况、病理分期以及雌激素受体、孕激素受体和人EGF受体2(human EGF receptor 2,HER-2)基因表达情况分组,比较VEGFR-3阳性表达率。结果 HE染色示两组组织芯片质量较好,能代表相应疾病组织病理学形态。免疫组织化学染色观察示,实验组中96例(55.5%)可见VEGFR-3表达阳性,对照组均未见阳性染色。不同年龄及雌激素受体、孕激素受体表达与否,VEGFR-3阳性表达率比较差异均无统计学意义(P>0.05),肿瘤越大、病理分期越高,VEGFR-3阳性表达率显著提高(P<0.05);腋窝淋巴结转移者及HER-2基因表达阳性者VEGFR-3阳性表达率明显高于各自阴性表达者(P<0.05)。结论 VEGFR-3在乳腺癌组织中的表达与淋巴结转移关系密切,有望成为新的判断预后指标及治疗靶点。
Objective To investigate the expression of vascular endothelial growth factor receptor 3 (VEGFR-3) in breast cancer and its relationship with the clinicopathological factors of breast cancer, and to provide evidence for the clinical treatment and prognosis of breast cancer. Methods Totally 173 paraffin-embedded specimens of breast cancer from March 2004 to June 2007 underwent breast cancer resection (experimental group). Tissue microarray was used to construct breast cancer tissue microarray. Hematoxylin-eosin The expression of VEGFR-3 was observed by histochemical staining. Paraffin-embedded specimens of 19 female patients undergoing resection of benign breast lesions at the same period were used as control (control group). The experimental group was divided into groups according to the age, tumor diameter, axillary lymph node metastasis, pathological stage and the gene expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER-2) -3 positive expression rate. Results Hematoxylin-eosin staining showed that the two groups of tissue chips were of good quality and could represent the histopathology of the corresponding disease. Immunohistochemical staining showed that VEGFR-3 was found in 96 (55.5%) of the experimental groups and no positive staining in the control group. There was no significant difference in the expression of estrogen receptor, progesterone receptor or VEGFR-3 between different age groups (P> 0.05). The higher the tumor size was, the higher the pathological stage was, the positive rate of VEGFR-3 (P <0.05). The positive rate of VEGFR-3 in axillary lymph node metastasis and HER-2 gene expression was significantly higher than that in negative expression (P <0.05). Conclusion The expression of VEGFR-3 in breast cancer is closely related to the lymph node metastasis, which is expected to become a new prognostic indicator and therapeutic target.